Thermo Fisher noted that its test is the first of its kind available in the US. The company added that its test also enables researches to detect the virus in samples over a much longer period of time than is possible with current detection methods.
"Since first learning about the Zika outbreak, we've worked closely with our colleagues at EUROIMMUN to mobilize resources and address this urgent need," said Mark Zacur, vice president and general manager of Thermo Fisher's healthcare market channel. "The EUROIMMUN test kits are an important step forward in the ongoing Zika response by facilitating a better understanding of the virus. We are pleased to have been chosen as their exclusive channel for making these tests available to our clinical research customers across the U.S."
Shares of Thermo Fisher showed no trades early Tuesday morning.
See more from Benzinga
- MarineMax Spikes 10% After Co. Announces Share Buyback Plan
- NV5 Global Announces Contract With Verizon, Shares Gain 4%
- Investors Disappointed With IAMGOLD's Business Update
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.